Cargando…
Fabry Disease: The Current Treatment Landscape
Fabry disease (FD) is a rare X-linked lysosomal storage disease based on a deficiency of α-galactosidase A (AGAL) caused by mutations in the α-galactosidase A gene (GLA). The lysosomal accumulation of glycosphingolipids, especially globotriaosylceramide (Gb(3)) and globotriaosylsphingosine (lyso-Gb(...
Autores principales: | Lenders, Malte, Brand, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102455/ https://www.ncbi.nlm.nih.gov/pubmed/33721270 http://dx.doi.org/10.1007/s40265-021-01486-1 |
Ejemplares similares
-
Fabry disease – a multisystemic disease with gastrointestinal manifestations
por: Lenders, Malte, et al.
Publicado: (2022) -
In Vitro and In Vivo Amenability to Migalastat in Fabry Disease
por: Lenders, Malte, et al.
Publicado: (2020) -
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease
por: Lenders, Malte, et al.
Publicado: (2021) -
Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
por: Lenders, Malte, et al.
Publicado: (2022) -
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
por: Lenders, Malte, et al.
Publicado: (2018)